Vaccine effectiveness
|
80%
|
93
|
Vaccine effectiveness (60–80%) + Vaccine utilization (10–66%)
|
88
|
60%
|
169
|
663
|
Vaccine utilization
|
66%
|
90
|
Vaccine effectiveness (60–80%) + Risk of perinatal transmission (HBeAg −) (2%–29%)
|
CS
|
10%
|
625
|
475
|
Risk of perinatal transmission (HBeAg −)
|
29%
|
CS
|
Vaccine effectiveness (60–80%) + Prevalence of HBV infection among mothers (2.5–10%) (10–66%)
|
CS
|
2%
|
373
|
421
|
Prevalence of HBV infection among mothers
|
10%
|
CS
|
Vaccine effectiveness (60%–80%) + Cost of medical care (from no cost to twice the cost of morbid states) (10–66%)
|
CS
|
2.5%
|
328
|
207
|
Cost of medical care
|
Twice the cost
|
CS
|
Vaccine effectiveness (60–80%) + Average cost per vaccinated child ($0.5–1.0) (10–66%)
|
13
|
No cost
|
158
|
262
|
Average cost per vaccinated child
|
$0.5
|
29
|
Vaccine effectiveness (60–80%) + Risk of perinatal transmission (HBeAg +) (14–56%)
|
32
|
$1.0
|
195
|
214
|
Risk of prinatal transmission (HBeAg +)
|
56%
|
51
|
Vaccine effectiveness (60–80%) + Prevalence of HBeAg in pregnant women (5–25%) (10–66%)
|
40
|
14%
|
156
|
202
|
Prevalence of HBeAg in pregnant women
|
25%
|
59
|
Vaccine effectiveness (60–80%) + Transition prob. of CAH to inactive carrier state (30–70%) (10–66%)
|
35
|
5%
|
146
|
174
|
Transition prob. of CAH to inactive carrier state
|
30%
|
60
| | |
70%
|
124
| | |